{"id":648732,"date":"2013-03-25T16:05:53","date_gmt":"2013-03-25T20:05:53","guid":{"rendered":"http:\/\/www.pehub.com\/?p=192947"},"modified":"2013-03-25T16:05:53","modified_gmt":"2013-03-25T20:05:53","slug":"theraclone-sciences-closes-another-14-mln-in-financing","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/648732","title":{"rendered":"Theraclone Sciences Closes Another $14 Mln in Financing"},"content":{"rendered":"

Theraclone Sciences<\/strong> said Monday it closed $14 million in additional financing. Existing investors — ARCH Venture Partners<\/strong>, Canaan Partners<\/strong>, MPM Capital<\/strong>, Healthcare Ventures<\/strong>, Alexandria Real Estate Equities<\/strong>, Amgen Ventures<\/strong>, Versant Ventures<\/strong> and Zenyaku Kogyo<\/strong> — committed $8 million equity. Another $6 million in venture debt was secured through a credit facility with MidCap Financial<\/strong> and Silicon Valley Bank<\/strong>. Seattle-based Theraclone develops novel therapeutic antibodies for the treatment of infectious disease and cancer.<\/p>\n

PRESS RELEASE
\nTheraclone Sciences, Inc., a therapeutic antibody discovery and development company, today announced a $14 million financing. $8 million in equity is committed from existing investors ARCH Venture Partners, Canaan Partners, MPM Capital, Healthcare Ventures, Alexandria Real Estate Equities, Amgen Ventures, Versant Ventures and Zenyaku Kogyo in a Series B Extension, bringing the total round to $50 million. An additional $6 million in venture debt has been secured through a credit facility with MidCap Financial and Silicon Valley Bank. Proceeds will help advance Theraclone\u2019s clinical programs and support ongoing discovery projects using Theraclone\u2019s I-STAR\u2122 technology platform, which is designed for the rapid screening and identification of rare, potent and therapeutically-relevant human antibodies.<\/p>\n

\u201cTheraclone has made significant progress with our lead development programs in flu and CMV as well as the discovery collaboration with Pfizer, demonstrating the strength of our R&D pipeline and technology platform,\u201d said Clifford J. Stocks, CEO of Theraclone. \u201cThe continued support from our investors represents a vote of confidence and reinforces Theraclone\u2019s ability to sustain our rapid pace of activity and development.\u201d<\/p>\n

About Theraclone Sciences<\/p>\n

Theraclone Sciences is a Seattle-based biotech focused on the development of novel therapeutic antibodies for the treatment of infectious disease and cancer. The Company\u2019s I-STAR\u2122 technology harnesses the power of the human immune system to identify rare, naturally evolved monoclonal antibodies from the blood cells of immunologically relevant human subjects. Theraclone has established discovery partnerships with Pfizer, Zenyaku Kogyo and the International AIDS Vaccine Research Initiative. In addition, the Company has two proprietary antibody programs in clinical development for pandemic and seasonal influenza and human cytomegalovirus (HCMV). www.theraclone-sciences.com.<\/p>\n

The post Theraclone Sciences Closes Another $14 Mln in Financing<\/a> appeared first on peHUB<\/a>.<\/p>\n

\n<\/img><\/a> <\/img><\/a> <\/img><\/a> <\/img><\/a> <\/img><\/a> <\/img><\/a> <\/img><\/a>\n<\/div>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Theraclone Sciences said Monday it closed $14 million in additional financing. Existing investors — ARCH Venture Partners, Canaan Partners, MPM Capital, Healthcare Ventures, Alexandria Real Estate Equities, Amgen Ventures, Versant Ventures and Zenyaku Kogyo — committed $8 million equity. Another $6 million in venture debt was secured through a credit facility with MidCap Financial and […]<\/p>\n","protected":false},"author":7426,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-648732","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/648732","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/7426"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=648732"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/648732\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=648732"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=648732"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=648732"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}